6 hours Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?The Motley Fool
Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its third-quarter earnings on Nov. 7.Usually, updates like thos…
Biotech · Earnings · Nasdaq 100
X